HER2-directed therapies, such as anti-HER2 monoclonal antibodies and kinase inhibitors (lapatinib [10]), have been extensively used for the treatment of HER2-positive breast cancer patients [11]. The gene discussed is ERBB2; the disease is breast carcinoma.